이 페이지는 자동 번역되었으며 번역의 정확성을 보장하지 않습니다. 참조하십시오 영문판 원본 텍스트의 경우.

Performance of Lumetry for Arterial Carbon Dioxide (paCO2) Assessment and Chronic Obstructive Pulmonary Disease (COPD) Screening

2026년 11월 16일 업데이트: Lumetry Diagnostics GmbH

Evaluation of the Clinical Performance of Lumetry for paCO2 Assessment and COPD Screening

The purpose of this clinical study is to evaluate how well the lumetry device performs in two areas: estimating the level of carbon dioxide in the arterial blood (paCO2) and screening for chronic obstructive pulmonary disease (COPD).

lumetry is a small handheld device that analyzes exhaled breath. Participants breathe normally into the device for 60 seconds. No forced or maximal breathing maneuvers are required for the lumetry measurement.

Today, the carbon dioxide level in the blood is usually measured with a blood gas analysis, which requires a blood sample. COPD is usually diagnosed with spirometry, a lung function test that requires maximal breathing effort and trained staff.

In this study, adults with COPD of different severity and adults without known lung disease each attend a single study visit. All participants perform one lumetry breath measurement and a standard lung function test (forced spirometry). Participants with COPD also give a small capillary blood sample from the earlobe for blood gas analysis, and some of them additionally have their carbon dioxide level measured through the skin (transcutaneous measurement). By comparing the lumetry results with these established methods, the study assesses how accurately the device estimates the carbon dioxide level in the blood. By comparing the lumetry COPD screening result with spirometry and the confirmed clinical diagnosis, the study assesses how reliably the device distinguishes between people with and without COPD.

The study is conducted at one hospital in Vienna, Austria, and will include 300 participants.

연구 개요

상태

아직 모집하지 않음

정황

개입 / 치료

연구 유형

중재적

등록 (추정된)

300

단계

  • 해당 없음

연락처 및 위치

이 섹션에서는 연구를 수행하는 사람들의 연락처 정보와 이 연구가 수행되는 장소에 대한 정보를 제공합니다.

연구 연락처

연구 연락처 백업

  • 이름: Nejla Hidic, BSc Biomedical Engineering
  • 전화번호: +4366488262391
  • 이메일: nejla.hidic@lumetry.at

연구 장소

참여기준

연구원은 적격성 기준이라는 특정 설명에 맞는 사람을 찾습니다. 이러한 기준의 몇 가지 예는 개인의 일반적인 건강 상태 또는 이전 치료입니다.

자격 기준

공부할 수 있는 나이

18년 (성인, 고령자)

건강한 자원 봉사자를 받아들입니다

예

연구 대상 성별

모두

설명

Inclusion Criteria:

  • Written informed consent
  • Age between 18 and 90 years
  • Diagnosed chronic obstructive pulmonary disease (COPD), stages GOLD I to IV, or no known lung function pathologies
  • Able to sit upright for the duration of the procedure without exhaustion
  • Women of childbearing potential: not breastfeeding and either a negative pregnancy test prior to the start of the investigation or use of a reliable method of contraception (intrauterine device or oral contraceptive pill) throughout the investigation. Women of childbearing potential are defined as women who have not undergone surgical sterilization (hysterectomy or bilateral oophorectomy) and are not postmenopausal (at least 12 months of amenorrhea in a woman over the age of 50 in the absence of other biological or physiological causes).

Exclusion Criteria:

  • Considered by the investigator to be inappropriate for inclusion or unlikely to comply with the requirements of the study
  • Lung disease other than COPD (e.g., asthma); participants with asthma-COPD overlap may be included
  • Previously documented chronic heart failure with an ejection fraction below 40%
  • Mental or physical inability to comply with time schedules and study procedures
  • Current participation in a clinical study that may affect breathing behaviour (medicinal product or medical device), or participation within 30 days prior to screening
  • Prior participation in this clinical investigation
  • Possible or confirmed pregnancy, or breastfeeding

공부 계획

이 섹션에서는 연구 설계 방법과 연구가 측정하는 내용을 포함하여 연구 계획에 대한 세부 정보를 제공합니다.

연구는 어떻게 설계됩니까?

디자인 세부사항

  • 주 목적: 특수 증상
  • 할당: 해당 없음
  • 중재 모델: 단일 그룹 할당
  • 마스킹: 없음(오픈 라벨)

무기와 개입

참가자 그룹 / 팔
개입 / 치료
실험적: Participants With and Without COPD

Adults with chronic obstructive pulmonary disease (COPD), stratified by severity (50 GOLD I/II, 50 GOLD III, 50 GOLD IV), and 150 adults without known lung function pathologies. All participants perform a single 60-second lumetry measurement of normal resting breathing, followed by forced spirometry. Participants with COPD additionally undergo arterialized capillary blood gas analysis, with a subgroup of 50 participants with COPD (GOLD III and IV) additionally undergoing transcutaneous carbon dioxide monitoring.

Handheld capnography and spirometry device that estimates the arterial partial pressure of carbon dioxide (paCO2) and provides a COPD screening result from a single 60-second measurement of normal resting breathing. The device also provides the end-tidal carbon dioxide value (petCO2), which serves as comparator for the paCO2 estimate.

Capillary blood sample from the arterialized earlobe, collected immediately after the lumetry measurement. Reference standard for paCO2. Performed in participants with COPD only.

Non-invasive measurement of carbon dioxide through the skin (tcPCO2), recorded as close in time as possible to the lumetry measurement and blood sampling. Comparator for paCO2 estimation. Performed in a subgroup of 50 participants with COPD.

Standard lung function test performed at the end of the study visit in all participants. Together with the documented clinical diagnosis, reference standard for the COPD screening result.

연구는 무엇을 측정합니까?

주요 결과 측정

결과 측정
측정값 설명
기간
Difference in Mean Absolute Deviation From Blood Gas paCO2 Between lumetry-Estimated paCO2 and End-Tidal Carbon Dioxide (petCO2)
기간: Day 1 (single study visit)

In participants with chronic obstructive pulmonary disease (COPD), the carbon dioxide level in the arterial blood (paCO2) estimated by lumetry is compared with the value measured in a capillary blood sample (blood gas analysis, reference standard). The average size of the difference, regardless of direction (mean absolute deviation), is calculated for lumetry and for the standard breath-based value (end-tidal carbon dioxide, petCO2). The outcome is the MAD of petCO2 minus the MAD of lumetry, so a positive value means lumetry is closer to the blood gas value.

Day 1 (single study visit)
Sensitivity of the lumetry COPD Screening Result
기간: Day 1 (single study visit)

Percentage of participants with COPD, as established by forced spirometry and documented clinical diagnosis (reference standard), who are classified as positive by the lumetry COPD screening result.

Day 1 (single study visit)
Specificity of the lumetry COPD Screening Result
기간: Day 1 (single study visit)

Percentage of participants without COPD, as established by forced spirometry and documented clinical diagnosis (reference standard), who are classified as negative by the lumetry COPD screening result.

Day 1 (single study visit)

2차 결과 측정

결과 측정
측정값 설명
기간
Standard Deviation of the Differences Between lumetry-Estimated paCO2 and Blood Gas paCO2
기간: Day 1 (single study visit)

In participants with chronic obstructive pulmonary disease (COPD), the difference between the lumetry-estimated arterial carbon dioxide level (paCO2) and the paCO2 measured by capillary blood gas analysis (reference standard) is calculated for each participant. The outcome is the standard deviation of these differences, describing the precision of the lumetry estimate. Unit: millimeters of mercury (mmHg).

Day 1 (single study visit)
Percentage of lumetry paCO2 Estimates Within 8 mmHg of Blood Gas paCO2
기간: Day 1 (single study visit)

In participants with COPD, the percentage of lumetry paCO2 estimates that differ by 8.0 millimeters of mercury (mmHg) or less in either direction from the paCO2 measured by capillary blood gas analysis (reference standard).

Day 1 (single study visit)
Difference in Mean Absolute Deviation From Blood Gas paCO2 Between lumetry-Estimated paCO2 and Transcutaneous Carbon Dioxide (tcPCO2)
기간: Day 1 (single study visit)

In a subgroup of 50 participants with COPD, the average size of the difference, regardless of direction (mean absolute deviation), from the paCO2 measured by capillary blood gas analysis (reference standard) is calculated for lumetry and for transcutaneous carbon dioxide monitoring (tcPCO2). The outcome is the difference between these two averages. Unit: millimeters of mercury (mmHg).

Day 1 (single study visit)

기타 결과 측정

결과 측정
측정값 설명
기간
Number of Participants With Adverse Events, Adverse Device Effects, or Device Deficiencies
기간: Day 1 (single study visit)

Number of participants with at least one adverse event, adverse device effect, or device deficiency related to the study procedures, recorded during the study visit.

Day 1 (single study visit)
Cross-Validated Sensitivity of a Re-Trained lumetry COPD Screening Algorithm
기간: Day 1 (single study visit)

Exploratory analysis. Sensitivity of a re-trained version of the lumetry machine learning algorithm for identifying participants with chronic obstructive pulmonary disease (COPD), estimated by stratified repeated k-fold cross-validation using the study data. Reference standard: forced spirometry and documented clinical diagnosis.

Day 1 (single study visit)
Cross-Validated Specificity of a Re-Trained lumetry COPD Screening Algorithm
기간: Day 1 (single study visit)

Exploratory analysis. Specificity of a re-trained version of the lumetry machine learning algorithm for identifying participants without COPD, estimated by stratified repeated k-fold cross-validation using the study data. Reference standard: forced spirometry and documented clinical diagnosis.

Day 1 (single study visit)
Cross-Validated Mean Absolute Deviation of Re-Trained lumetry paCO2 Estimates From Blood Gas paCO2
기간: Day 1 (single study visit)

Exploratory analysis. Average size of the difference, regardless of direction (mean absolute deviation), between the arterial carbon dioxide level (paCO2) estimated by a re-trained version of the lumetry machine learning algorithm and the paCO2 measured by capillary blood gas analysis, estimated by stratified repeated k-fold cross-validation in participants with COPD. Unit: millimeters of mercury (mmHg).

Day 1 (single study visit)

공동 작업자 및 조사자

여기에서 이 연구와 관련된 사람과 조직을 찾을 수 있습니다.

스폰서

협력자

수사관

  • 수석 연구원: Arschang Valipour, Prim. Priv. -Doz. Dr., Klinik Floridsdorf, Department of Respiratory and Critical Care Medicine

간행물 및 유용한 링크

연구에 대한 정보 입력을 담당하는 사람이 자발적으로 이러한 간행물을 제공합니다. 이것은 연구와 관련된 모든 것에 관한 것일 수 있습니다.

일반 간행물

  • Klemm et al. Predicting arterial pCO2 using capnographic recordings - A pilot study using a novel breath analysis device. Eur Respir J. 2025; 66(Suppl 69): PA2529. doi:10.1183/13993003.congress-2025.PA2529

연구 기록 날짜

이 날짜는 ClinicalTrials.gov에 대한 연구 기록 및 요약 결과 제출의 진행 상황을 추적합니다. 연구 기록 및 보고된 결과는 공개 웹사이트에 게시되기 전에 특정 품질 관리 기준을 충족하는지 확인하기 위해 국립 의학 도서관(NLM)에서 검토합니다.

연구 주요 날짜

연구 시작 (추정된)

2026년 12월 1일

기본 완료 (추정된)

2027년 12월 1일

연구 완료 (추정된)

2027년 12월 1일

연구 등록 날짜

최초 제출

2026년 11월 16일

QC 기준을 충족하는 최초 제출

2026년 11월 16일

처음 게시됨 (실제)

2026년 11월 20일

연구 기록 업데이트

마지막 업데이트 게시됨 (실제)

2026년 11월 20일

QC 기준을 충족하는 마지막 업데이트 제출

2026년 11월 16일

마지막으로 확인됨

2026년 11월 1일

추가 정보

이 연구와 관련된 용어

개별 참가자 데이터(IPD) 계획

개별 참가자 데이터(IPD)를 공유할 계획입니까?

아니요

약물 및 장치 정보, 연구 문서

미국 FDA 규제 의약품 연구

아니

미국 FDA 규제 기기 제품 연구

아니

이 정보는 변경 없이 clinicaltrials.gov 웹사이트에서 직접 가져온 것입니다. 귀하의 연구 세부 정보를 변경, 제거 또는 업데이트하도록 요청하는 경우 register@clinicaltrials.gov. 문의하십시오. 변경 사항이 clinicaltrials.gov에 구현되는 즉시 저희 웹사이트에도 자동으로 업데이트됩니다. .